Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.

Date publication

décembre 2021

Journal

Therapie

Auteurs

Membres identifiés du Cancéropôle Est :
Pr JOLLY Damien

Tous les auteurs :
Jarrion Q, Azzouz B, Robinson J, Jolly D, Vallet C, Trenque T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35027238

Résumé

Since the expiry of the patents on originator anti-TNF agents in Europe, France has authorized the sale of biosimilars. The penetration rate of anti-TNF agents and their biosimilars, and the cost savings driven by the introduction of biosimilars appears to vary widely. This study aimed to describe the market share of anti-TNFs and their biosimilars, and the cost savings generated by the introduction of biosimilars in French hospitals 5 years ago.

Mots clés

Biosimilar pharmaceuticals, Commerce, Cost savings, Hospitals, Tumor necrosis factor inhibitors

Référence

Therapie. 2021 Dec 14;: